<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02511145</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR.40221E</org_study_id>
    <secondary_id>2013‐003371‐35</secondary_id>
    <nct_id>NCT02511145</nct_id>
  </id_info>
  <brief_title>Comparison of Mechanical Penetration Enhancers on Metvixia Skin Penetration</brief_title>
  <official_title>Exploratory Study to Compare Mechanical Penetration Enhancers on Metvixia Skin Penetration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma R&amp;D</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exploratory, mono-center, randomized, intra-individual, controlled trial involving healthy
      volunteers to compare the effect on MAL penetration into the skin following various
      mechanical penetration enhancement techniques.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At baseline, each mini-zone was selected and randomly assigned to a pretreatment: 3 zones
      with microneedling Dermaroller®, 3 zones with ablative fractional CO2 Laser, and 3 zones with
      no pretreatment. After performing pretreatment, MAL cream was applied on the 6 assigned
      mini-zones for 3 hours incubation. Each condition was tested with and without occlusion. The
      three mini-zones with no product applied were used to perform biophysics measures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fluorescence of protoporphyrin IX (PpIX)</measure>
    <time_frame>3 hours</time_frame>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Microneedles pretreatment and Metvixia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>minizone with Microneedles pretreatment and Metvixia cream application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microneedles pretreatment and Metvixia under occlusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>minizone with Microneedles pretreatment and Metvixia cream application with occlusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laser pretreatment and Metvixia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>minizone with laser pretreatment and Metvixia cream application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laser pretreatment and Metvixia under occlusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>minizone with Laser pretreatment and Metvixia cream application with occlusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metvixia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>minizone with Metvixia cream application, without pretreatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metvixia under occlusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>minizone with Metvixia cream application under occlusion, without pretreatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microneedles pretreatment only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>minizone with Microneedles pretreatment only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laser pretreatment only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>minizone with Laser pretreatment only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal skin</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Normal skin control mini-zone</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>occlusive bandage</intervention_name>
    <arm_group_label>Microneedles pretreatment and Metvixia under occlusion</arm_group_label>
    <arm_group_label>Laser pretreatment and Metvixia under occlusion</arm_group_label>
    <arm_group_label>Metvixia under occlusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ablative fractional CO2 laser pretreatment</intervention_name>
    <arm_group_label>Laser pretreatment and Metvixia</arm_group_label>
    <arm_group_label>Laser pretreatment and Metvixia under occlusion</arm_group_label>
    <arm_group_label>Laser pretreatment only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microneedles pretreatment</intervention_name>
    <arm_group_label>Microneedles pretreatment and Metvixia</arm_group_label>
    <arm_group_label>Microneedles pretreatment and Metvixia under occlusion</arm_group_label>
    <arm_group_label>Microneedles pretreatment only</arm_group_label>
    <other_name>Dermaroller</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>METVIXIA Cream</intervention_name>
    <arm_group_label>Microneedles pretreatment and Metvixia</arm_group_label>
    <arm_group_label>Microneedles pretreatment and Metvixia under occlusion</arm_group_label>
    <arm_group_label>Laser pretreatment and Metvixia</arm_group_label>
    <arm_group_label>Laser pretreatment and Metvixia under occlusion</arm_group_label>
    <arm_group_label>Metvixia</arm_group_label>
    <arm_group_label>Metvixia under occlusion</arm_group_label>
    <other_name>MAL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female of non childbearing potential, who is at least 18 years of age or older
             at screening visit.

          -  The subject has a skin phototype of I to III on Fitzpatrick's scale (Fitzpatrick et
             al., 1993) at screening visit.

          -  Subject should have 9 mini zone areas on the back that will be able to receive
             pre-treatments according to protocol. (checked at Screening visit, and assigned at
             Baseline visit)

          -  Female of non childbearing potential (postmenopausal [absence of menstrual bleeding
             for 1 year prior to screening visit, without any other medical reason], hysterectomy
             or bilateral oophorectomy).

        Exclusion Criteria:

          -  Subject with porphyria,

          -  Subject with past history of skin cancer, or current clinical diagnosis of other skin
             disease (including non-melanoma skin cancer), or tattoos, or cheloid and hypertrophic
             scars on the test zones, which, in the opinion of the investigator, might interfere
             with the interpretation of the clinical results,

          -  Any uncontrolled or serious disease, or any medical or surgical condition, that may
             either interfere with the interpretation of the clinical trial results, and/or put the
             subject at significant risk (according to Investigator's judgment) if he/she
             participates in the clinical trial.

          -  Known or suspected allergies or sensitivities to any components of any of the study
             drugs (see Product label).

          -  The subject has received, applied or taken some specific treatments within specified
             time frame prior to the baseline visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2015</study_first_submitted>
  <study_first_submitted_qc>July 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2015</study_first_posted>
  <last_update_submitted>July 30, 2015</last_update_submitted>
  <last_update_submitted_qc>July 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyl 5-aminolevulinate</mesh_term>
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

